JP2018528945A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528945A5 JP2018528945A5 JP2018510089A JP2018510089A JP2018528945A5 JP 2018528945 A5 JP2018528945 A5 JP 2018528945A5 JP 2018510089 A JP2018510089 A JP 2018510089A JP 2018510089 A JP2018510089 A JP 2018510089A JP 2018528945 A5 JP2018528945 A5 JP 2018528945A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- measuring
- renal
- composition
- kidney
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 18
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 12
- 239000002777 nucleoside Substances 0.000 claims 10
- 108091034117 Oligonucleotide Proteins 0.000 claims 8
- 210000003734 kidney Anatomy 0.000 claims 7
- 229940109239 creatinine Drugs 0.000 claims 6
- 206010020772 Hypertension Diseases 0.000 claims 5
- 210000004369 blood Anatomy 0.000 claims 5
- 239000008280 blood Substances 0.000 claims 5
- 125000003835 nucleoside group Chemical group 0.000 claims 5
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims 4
- 206010001580 Albuminuria Diseases 0.000 claims 4
- 206010038490 Renal pain Diseases 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 4
- 230000006866 deterioration Effects 0.000 claims 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 208000026372 Congenital cystic kidney disease Diseases 0.000 claims 3
- 208000026292 Cystic Kidney disease Diseases 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims 3
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- 230000024924 glomerular filtration Effects 0.000 claims 3
- 208000006750 hematuria Diseases 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 208000030761 polycystic kidney disease Diseases 0.000 claims 3
- 210000002700 urine Anatomy 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 102000005862 Angiotensin II Human genes 0.000 claims 2
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 2
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 2
- 101800000733 Angiotensin-2 Proteins 0.000 claims 2
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 claims 2
- 206010011732 Cyst Diseases 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000013382 Gelatinases Human genes 0.000 claims 2
- 108010026132 Gelatinases Proteins 0.000 claims 2
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims 2
- 101710185991 Hepatitis A virus cellular receptor 1 homolog Proteins 0.000 claims 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims 2
- 102000019298 Lipocalin Human genes 0.000 claims 2
- 108050006654 Lipocalin Proteins 0.000 claims 2
- 206010061481 Renal injury Diseases 0.000 claims 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 2
- 102000004136 Vasopressin Receptors Human genes 0.000 claims 2
- 108090000643 Vasopressin Receptors Proteins 0.000 claims 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims 2
- 229950006323 angiotensin ii Drugs 0.000 claims 2
- 208000031513 cyst Diseases 0.000 claims 2
- 238000000502 dialysis Methods 0.000 claims 2
- 230000003907 kidney function Effects 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 108091091751 miR-17 stem-loop Proteins 0.000 claims 2
- 108091069239 miR-17-2 stem-loop Proteins 0.000 claims 2
- 210000000440 neutrophil Anatomy 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 239000003087 receptor blocking agent Substances 0.000 claims 2
- 229960002930 sirolimus Drugs 0.000 claims 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- IHLOTZVBEUFDMD-UUOKFMHZSA-N 7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,2-dioxo-1h-imidazo[4,5-c][1,2,6]thiadiazin-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NS(=O)(=O)NC2=O)=C2N=C1 IHLOTZVBEUFDMD-UUOKFMHZSA-N 0.000 claims 1
- 208000002814 Autosomal Recessive Polycystic Kidney Diseases 0.000 claims 1
- 208000017354 Autosomal recessive polycystic kidney disease Diseases 0.000 claims 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims 1
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 102400000739 Corticotropin Human genes 0.000 claims 1
- 101800000414 Corticotropin Proteins 0.000 claims 1
- 229940097420 Diuretic Drugs 0.000 claims 1
- 108010061435 Enalapril Proteins 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 101100029888 Homo sapiens PKD1 gene Proteins 0.000 claims 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 claims 1
- -1 LNA nucleoside Chemical class 0.000 claims 1
- 108010007859 Lisinopril Proteins 0.000 claims 1
- 239000005480 Olmesartan Substances 0.000 claims 1
- 101150056230 PKD1 gene Proteins 0.000 claims 1
- 206010062237 Renal impairment Diseases 0.000 claims 1
- 102000005157 Somatostatin Human genes 0.000 claims 1
- 108010056088 Somatostatin Proteins 0.000 claims 1
- 238000011374 additional therapy Methods 0.000 claims 1
- 239000000674 adrenergic antagonist Substances 0.000 claims 1
- 229960004530 benazepril Drugs 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical group C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims 1
- 229960003736 bosutinib Drugs 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 229960000932 candesartan Drugs 0.000 claims 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical group SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 1
- 229960000258 corticotropin Drugs 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 229960000873 enalapril Drugs 0.000 claims 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 1
- 208000028208 end stage renal disease Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- 229960004563 eprosartan Drugs 0.000 claims 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 229960002490 fosinopril Drugs 0.000 claims 1
- 239000003668 hormone analog Substances 0.000 claims 1
- 229960002198 irbesartan Drugs 0.000 claims 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 1
- 229960002394 lisinopril Drugs 0.000 claims 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims 1
- 229960004773 losartan Drugs 0.000 claims 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 229960005117 olmesartan Drugs 0.000 claims 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims 1
- 101150112863 pkd2 gene Proteins 0.000 claims 1
- 231100000857 poor renal function Toxicity 0.000 claims 1
- 229960001455 quinapril Drugs 0.000 claims 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims 1
- 229960003401 ramipril Drugs 0.000 claims 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims 1
- 239000002461 renin inhibitor Substances 0.000 claims 1
- 229940086526 renin-inhibitors Drugs 0.000 claims 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
- 229960000553 somatostatin Drugs 0.000 claims 1
- 229960002256 spironolactone Drugs 0.000 claims 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical group C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims 1
- 229960005187 telmisartan Drugs 0.000 claims 1
- GYHCTFXIZSNGJT-UHFFFAOYSA-N tolvaptan Chemical group CC1=CC=CC=C1C(=O)NC(C=C1C)=CC=C1C(=O)N1C2=CC=C(Cl)C=C2C(O)CCC1 GYHCTFXIZSNGJT-UHFFFAOYSA-N 0.000 claims 1
- 229960001256 tolvaptan Drugs 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 229960004699 valsartan Drugs 0.000 claims 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562210031P | 2015-08-26 | 2015-08-26 | |
| US62/210,031 | 2015-08-26 | ||
| PCT/US2016/048603 WO2017035319A1 (en) | 2015-08-26 | 2016-08-25 | Methods for treatment of polycystic kidney disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018528945A JP2018528945A (ja) | 2018-10-04 |
| JP2018528945A5 true JP2018528945A5 (cg-RX-API-DMAC7.html) | 2019-10-03 |
| JP6929269B2 JP6929269B2 (ja) | 2021-09-01 |
Family
ID=56855838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018510089A Active JP6929269B2 (ja) | 2015-08-26 | 2016-08-25 | 多発性嚢胞腎の処置のための方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10633657B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3340993B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6929269B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20250049446A (cg-RX-API-DMAC7.html) |
| CN (2) | CN108135922A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016312590B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2995996A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3340993T5 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2954151T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL257596B (cg-RX-API-DMAC7.html) |
| MA (1) | MA44836A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018002354A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2742300C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017035319A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102759999B1 (ko) * | 2016-12-05 | 2025-02-03 | 레굴루스 테라퓨틱스 인크 | 다낭성 신장 질환의 치료를 위한 변형된 올리고뉴클레오타이드 |
| EP3548011B1 (en) * | 2016-12-05 | 2023-06-14 | Regulus Therapeutics Inc. | Methods for treatment of polycystic kidney disease |
| WO2020038968A1 (en) | 2018-08-23 | 2020-02-27 | Roche Innovation Center Copenhagen A/S | Microrna-134 biomarker |
| WO2024026354A2 (en) * | 2022-07-27 | 2024-02-01 | The General Hospital Corporation | Methods and compositions for use in treating autosomal recessive polycystic kidney disease (arpkd) |
| AU2024304872A1 (en) * | 2023-06-16 | 2025-12-18 | PYC Therapeutics Limited | Compositions and methods for treatment of kidney disease |
| WO2025110217A1 (ja) * | 2023-11-22 | 2025-05-30 | 国立大学法人東海国立大学機構 | 嚢胞性腎疾患の予防及び／又は治療剤 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005013901A2 (en) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| CA2558020A1 (en) | 2004-03-17 | 2005-09-29 | Novartis Ag | Use of renin inhibitors in therapy |
| WO2007126150A1 (ja) * | 2006-04-27 | 2007-11-08 | National University Corporation Nagoya University | 癌の新規治療用組成物 |
| US20120283411A9 (en) * | 2006-06-29 | 2012-11-08 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| CA2927045A1 (en) | 2006-10-03 | 2008-04-10 | Muthiah Manoharan | Lipid containing formulations |
| US20090105174A1 (en) * | 2007-04-20 | 2009-04-23 | Amgen Inc. | Nucleic acids hybridizable to micro rna and precursors thereof |
| WO2009143403A1 (en) * | 2008-05-23 | 2009-11-26 | Targacept, Inc. | Combination therapy for the management hypertension |
| WO2014082644A1 (en) * | 2012-11-30 | 2014-06-05 | WULFF, Peter, Samuel | Circular rna for inhibition of microrna |
| JP2016534069A (ja) * | 2013-10-24 | 2016-11-04 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | Ｈｄａｃ６阻害剤での多嚢胞性疾患の治療 |
| JP2017511694A (ja) * | 2014-02-12 | 2017-04-27 | トーマス・ジェファーソン・ユニバーシティ | マイクロｒｎａ阻害剤を使用するための組成物および方法 |
| KR102759999B1 (ko) | 2016-12-05 | 2025-02-03 | 레굴루스 테라퓨틱스 인크 | 다낭성 신장 질환의 치료를 위한 변형된 올리고뉴클레오타이드 |
| EP3548011B1 (en) | 2016-12-05 | 2023-06-14 | Regulus Therapeutics Inc. | Methods for treatment of polycystic kidney disease |
-
0
- MA MA044836A patent/MA44836A/fr unknown
-
2016
- 2016-08-25 EP EP16760627.6A patent/EP3340993B1/en active Active
- 2016-08-25 IL IL257596A patent/IL257596B/en unknown
- 2016-08-25 DK DK16760627.6T patent/DK3340993T5/da active
- 2016-08-25 WO PCT/US2016/048603 patent/WO2017035319A1/en not_active Ceased
- 2016-08-25 EP EP23179064.3A patent/EP4268891A3/en not_active Withdrawn
- 2016-08-25 CN CN201680049290.6A patent/CN108135922A/zh active Pending
- 2016-08-25 AU AU2016312590A patent/AU2016312590B2/en active Active
- 2016-08-25 RU RU2018108206A patent/RU2742300C2/ru active
- 2016-08-25 MX MX2018002354A patent/MX2018002354A/es unknown
- 2016-08-25 US US15/753,865 patent/US10633657B2/en active Active
- 2016-08-25 JP JP2018510089A patent/JP6929269B2/ja active Active
- 2016-08-25 ES ES16760627T patent/ES2954151T3/es active Active
- 2016-08-25 KR KR1020257010343A patent/KR20250049446A/ko active Pending
- 2016-08-25 CA CA2995996A patent/CA2995996A1/en active Pending
- 2016-08-25 KR KR1020187007997A patent/KR20180080181A/ko not_active Ceased
- 2016-08-25 CN CN202111177217.6A patent/CN114404440A/zh active Pending
-
2020
- 2020-03-19 US US16/823,904 patent/US11168325B2/en active Active
-
2021
- 2021-10-05 US US17/494,234 patent/US20220025372A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018528945A5 (cg-RX-API-DMAC7.html) | ||
| JP2015536301A5 (cg-RX-API-DMAC7.html) | ||
| Darisipudi et al. | Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease | |
| RU2018108206A (ru) | Способы лечения поликистозной болезни почек | |
| Szabo et al. | Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat | |
| Wilflingseder et al. | miR-182-5p inhibition ameliorates ischemic acute kidney injury | |
| JP2019536803A5 (cg-RX-API-DMAC7.html) | ||
| JP2019501935A5 (cg-RX-API-DMAC7.html) | ||
| Kusumoto et al. | Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models | |
| HRP20170557T2 (hr) | Mikrorna spojevi i postupci za modulaciju aktivnosti mir-21 | |
| Perico et al. | Pathophysiology of disease progression in proteinuric nephropathies | |
| Fan et al. | Augmentation of intrarenal angiotensin II levels in uninephrectomized aldosterone/salt-treated hypertensive rats; renoprotective effects of an ultrahigh dose of olmesartan | |
| WO2019028055A1 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AC T-LYMPHOBLASTIC LYMPHOBLASTIC LEUKEMIA | |
| Cao et al. | Febuxostat prevents renal interstitial fibrosis by the activation of BMP-7 signaling and inhibition of USAG-1 expression in rats | |
| Roberts et al. | Adenosine receptor expression in the development of renal fibrosis following ischemic injury | |
| CA2972076A1 (en) | Combination of raf inhibitors and aurora kinase inhibitors | |
| JP2020518633A5 (cg-RX-API-DMAC7.html) | ||
| Budu et al. | Renal fibrosis due to multiple cisplatin treatment is exacerbated by kinin B1 receptor antagonism | |
| McFarlane et al. | Improving outcomes in diabetes and chronic kidney disease: the basis for Canadian guidelines | |
| Qian et al. | Inhibition of WISE preserves renal allograft function | |
| Tan et al. | Protective effects of FR167653 on chronic allograft nephropathy by inhibiting p38 MAPK in rats | |
| SHELDON HIRSCH | An update on proteinuric chronic kidney disease: The dual-goal approach | |
| Levy et al. | Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials | |
| JP2020114857A (ja) | Ｒａｆ阻害剤及びタキサンの組み合わせ | |
| Chadjichristos et al. | Reversibility of renal fibrosis |